PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PRT-2527’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PRT-2527 overview
PRT-2527 is under development for the treatment of relapsed/refractory hematologic malignancies including, diffuse large b-cell lymphoma, follicular lymphoma, primary mediastinal b-cell lymphoma, aggressive B-cell lymphoma subtypes, T-Cell lymphomas, mantle cell lymphoma (MCL), and chronic lymphocytic lymphoma (CLL)/small lymphocytic lymphoma (SLL), including Richter's syndrome, acute myelocytic leukemia, non-small cell lung cancer and solid tumors including sarcomas, human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer), hormone refractory (castration resistant, androgen-independent) prostate cancer, breast cancer and other cancers with genomic alterations that lead to MYC dependence. It is administered through intravenous route. The drug candidate acts by targeting cyclin dependent kinase 9 (CDK9).
It was also under development for the treatment of triple-negative breast cancer (TNBC), synovial sarcoma.
Prelude Therapeutics overview
Prelude Therapeutics (Prelude) is a clinical-stage oncology company that provides drug discovery and development for the treatment of cancers. The company pipeline products include PRT3789, PRT2527 and PRT3645 for the indication including solid Tumors, and Heme Malignancies. Its other pipelines include pipeline includes an IV-administered, potent and highly selective SMARCA2 degrader, PRT3789, a preclinical oral SMARCA2 selective degrader, PRT7732, a potent and highly selective CDK9 inhibitor, PRT2527, and a next-generation CDK4/6 inhibitor, PRT3645. The company collaborates with AbCellera Biologics. on an early-stage discovery program. Prelude is headquartered in Wilmington, Delaware, the US.
For a complete picture of PRT-2527’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
